Semaglutide (5 mg) is a long-acting synthetic analog of glucagon-like peptide-1 (GLP-1), designed for controlled laboratory investigation. It incorporates targeted amino acid substitutions and a fatty acid side chain to support extended interaction in experimental systems.
With a molecular weight of 4113.6 g/mol, Semaglutide is typically supplied as a ≥95% pure, lyophilized powder in a sealed research-grade vial. In research, it mimics prolonged GLP-1 activity, allowing researchers to observe signaling behaviors distinct from those of the short-lived native hormone.
Semaglutide (5 mg) Key Features & Specs
- Subcategory: Weight Loss & Metabolic Peptides
- Strength: 5 mg
- CAS: 910463-68-2
- Chemical Formula: C₁₈₇H₂₉₁N₄₅O₅₉
- Molecular Weight: 4113.6 g/mol
- Peptide Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-OH
- Synonyms: NN9535
For laboratory research use only.
Semaglutide (5 mg) Research Uses
Semaglutide (5 mg) is being investigated for its effects on metabolic and endocrine function. Investigations often focus on how this peptide influences glucose-related processes, hormone-mediated signaling, and energy regulation under controlled conditions.
In laboratory models, it is used to examine receptor binding activity, intracellular signaling, and broader metabolic communication between tissues. Ongoing research aims to better understand how peptide analogs interact with regulatory systems involved in nutrient processing and cellular responses.
Semaglutide (5 mg) Insights & Observed Findings
Preclinical and in vitro studies typically use structured dosing regimens tailored to specific experimental models, including low-dose exposures to evaluate signaling responses and receptor engagement over time.
Findings from metabolic research often highlight changes in metabolic markers and signaling activity, particularly in glucose dynamics and endocrine communication. Reported observations can vary depending on study conditions, including model selection, study duration, and analytical methods.
Semaglutide (5 mg) Handling & Storage
Store Semaglutide (5 mg) at 2–8°C for short-term use, with long-term storage at ≤–20°C when required. The vial should remain sealed until preparation and be protected from light to maintain sample integrity.
Before reconstitution, allow the vial to reach appropriate handling conditions to reduce condensation. After reconstitution using sterile techniques, store the solution at 2–8°C and follow standard laboratory protocols. Avoid repeated freeze-thaw cycles and minimize exposure to moisture and contaminants.
Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
References
- Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. Published 2024 Jul 24. doi:10.3389/fendo.2024.1431292
- Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. doi:10.1016/S2468-1253(23)00068-7
- Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(3):521-539. doi:10.1007/s11154-021-09699-1
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Published 2019 Apr 12. doi:10.3389/fendo.2019.00155